Purpose Immunocompromised patients have a potentially increased risk for progression to
severe COVID-19 and prolonged replication of SARS-CoV-2. This post hoc analysis …

Introduction The randomized, placebo-controlled, double-blind MOVe-OUT trial
demonstrated molnupiravir (800 mg every 12 h for 5 days) as safe and effective for …

Background The role of molnupiravir for coronavirus disease 2019 (COVID-19) treatment is
unclear. Methods We conducted a systematic review until 1 November 2022 searching for …

Background New treatments are needed to reduce the risk of progression of coronavirus
disease 2019 (Covid-19). Molnupiravir is an oral, small-molecule antiviral prodrug that is …

Objectives AGILE is a Phase Ib/IIa platform for rapidly evaluating COVID-19 treatments. In
this trial (NCT04746183) we evaluated the safety and optimal dose of molnupiravir in …

Background The effects of molnupiravir in treating patients with non-severe COVID-19
remain uncertain. Objectives To evaluate the efficacy and safety of molnupiravir in adult …

Background Molnupiravir has been considered a promising candidate for COVID-19. Its
efficacy and safety in non-severe COVID-19 patients and the differences between patients …

Background Safe and effective oral treatments are needed to improve clinical outcomes for
nonhospitalized patients with Covid-19. Molnupiravir is an orally administered, small …

Since December 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has
rapidly resulted in a global pandemic with approximately 4 million deaths. Effective oral …

Background: Molnupiravir is an oral prodrug with antiviral activity against severe acute
respiratory syndrome coronavirus-2 (SARS-CoV-2). Molnupiravir was initially developed for …